ISMG Editors: The Battle Over Access to Frontier AI Models

Artificial Intelligence & Machine Learning , Governance & Risk Management , Next-Generation Technologies & Secure Development ISMG Editors: The Battle Over Access to Frontier AI Models Also: Washington's AI Policy Divide, FDA's Push for AI-Driven Clinical Trials Anna Delaney (annamadeline) • May 8, 2026     Share Post Share Credit Eligible Get Permission Clockwise, from top left: Anna Delaney, Marianne Kolbasuk McGee, Michael Novinson and Chris Riotta In this week's panel, four ISMG editors discussed the battle over who gets to access powerful AI cybersecurity models, policy issues unfolding in Washington over AI-driven cyber defenses, and how the FDA is beginning to test AI-supported real-time clinical trials to speed up drug development. See Also: Why Every AI Decision Begins With DNS The panelists - Anna Delaney, executive director, productions; Marianne Kolbasuk McGee, executive editor, HealthcareInfoSecurity; Michael Novinson, executive editor, ISMG Business; and Chris Riotta, managing editor, GovInfoSecurity - discussed: The contrasting approaches taken by Anthropic and OpenAI in granting access to advanced AI cybersecurity models, highlighting the tension between safety, competitive strategy and control over emerging frontier AI capabilities; The growing policy divide in Washington over access to powerful frontier AI cybersecurity models such as Anthropic’s Mythos, as the White House weighs national security advantages against the risks of broader deployment and insufficient safeguards; How the U.S. Food and Drug Administration is piloting AI-supported real-time clinical trials to accelerate drug development by improving efficiency, patient monitoring and decision-making in early-stage trials. The ISMG Editors' Panel runs weekly. Don't miss our previous installments, including the April 24 edition on the push for AI innovation and the fallout and the May 1 edition on North Korea's latest crypto heists.